Von Hippel-Lindau Disease Market

Market Overview:

The 7 major Von Hippel-Lindau disease markets are expected to exhibit a CAGR of 7.97% during 2024-2034.

The Von Hippel-Lindau disease market has been comprehensively analyzed in IMARC's new report titled "Von Hippel-Lindau Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Von Hippel-Lindau disease (VHL) refers to a rare genetic disorder that affects the growth of tumors and cysts in different parts of the body. It is caused by mutations in the VHL gene, which provides instructions for making a protein that helps to regulate cell growth and division. When this gene is mutated, it can lead to the development of abnormal growth in various organs, such as the eyes, brain, spinal cord, kidneys, pancreas, and adrenal glands. The common indications associated with this condition include headaches, hearing loss or ringing in the ears, high blood pressure, impaired balance, loss of muscle strength or coordination, vomiting, nausea, abdominal pain, vision problems, etc. Diagnosing this ailment is typically based on a review of the patient’s medical history and clinical features. Genetic testing that identifies changes in chromosomes, genes, or proteins is also recommended among the population. The healthcare provider may further adopt diagnostic procedures, like magnetic resonance imaging (MRI) and computed tomography (CT) scans, to examine the affected site and confirm a diagnosis.

The increasing prevalence of hereditary conditions that produce DNA abnormalities and uncontrolled growth of harmful cells in the body is primarily driving the Von Hippel-Lindau disease market. In addition to this, the escalating application of exome sequencing tests, which can detect genetic variations associated with birth defects and developmental delays, thereby providing an accurate diagnosis in patients, is also augmenting the market growth. Furthermore, the widespread adoption of stereotactic radiation therapy, since it delivers an adequate amount of radiation to the tumor in a shorter period of time than other traditional treatments, is creating a positive outlook for the market. Additionally, the rising demand for hypoxia-inducible factor-2 alpha inhibitor that works by declining transcription and expression of target genes related to angiogenesis, cellular proliferation, and tumor progression, is acting as another significant growth-inducing factor. Besides this, the emerging popularity of cryotherapy for treating advanced conditions, since it can fully obliterate the tumor and promote overall survival, is expected to drive the Von Hippel-Lindau disease market in the coming years. 

IMARC Group's new report provides an exhaustive analysis of the Von Hippel-Lindau disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Von Hippel-Lindau disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Von Hippel-Lindau disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Von Hippel-Lindau disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Von Hippel-Lindau disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Von Hippel-Lindau disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

Late-Stage Pipeline Drugs

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Von Hippel-Lindau disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the Von Hippel-Lindau disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the Von Hippel-Lindau disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of Von Hippel-Lindau disease by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with Von Hippel-Lindau disease across the seven major markets?
• What is the size of the Von Hippel-Lindau disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of Von Hippel-Lindau disease?
• What will be the growth rate of patients across the seven major markets?
   

Von Hippel-Lindau Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Von Hippel-Lindau disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Von Hippel-Lindau disease market?
• What are the key regulatory events related to the Von Hippel-Lindau disease market?
• What is the structure of clinical trial landscape by status related to the Von Hippel-Lindau disease market?
• What is the structure of clinical trial landscape by phase related to the Von Hippel-Lindau disease market?
• What is the structure of clinical trial landscape by route of administration related to the Von Hippel-Lindau disease market?